Dabrafenib (GSK2118436)

Catalog No.S2807

Dabrafenib (GSK2118436) Chemical Structure

Molecular Weight(MW): 519.56

Dabrafenib (GSK2118436) is a mutant BRAFV600 specific inhibitor with IC50 of 0.8 nM in cell-free assays, with 4- and 6-fold less potency against B-Raf(wt) and c-Raf, respectively.

Size Price Stock Quantity  
In DMSO USD 180 In stock
USD 90 In stock
USD 130 In stock
USD 170 In stock
USD 270 In stock
USD 400 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

5 Customer Reviews

  • A375P cells were treated with vehicle, the BRAF inhibitor GSK2118436, the MEK inhibitor GSK1120212, 10 uM HCQ, or the indicated combinations. Shown are 48-hour immunoblots directed against the indicated proteins.

    J Clin Invest 2014 24(3), 1406-17. Dabrafenib (GSK2118436) purchased from Selleck.

    Levels of pERK and tERK in the CLL cells derived from PBMC were measured by Western blot. We used vemurafenib, dabrafenib, and trametinib (0.07 uM) as indicated. One of 3 independent experiments with similar results is shown. CLL cells exposed to dabrafenib or vemurafenib had an elevated pERK/tERK ratio as compared with vehicle (P < 0.01).

    J Clin Invest 2014 124(11), 5074-84. Dabrafenib (GSK2118436) purchased from Selleck.

  • The effects of inhibitors of mutant BRAFV600 inhibitor dabrafenib on cancer cell growth were evaluated by the MTT assay. Cell growth inhibition of FRO and SW1736 cell lines induced by dabrafenib.

    Transl Res 2014 10.1016/j.trsl.2014.06.005. Dabrafenib (GSK2118436) purchased from Selleck.

    Dabrafenib alleviates acetaminophen-induced hepatotoxicity in mice. Mice were treated with 300 mg/kg acetaminophen (i.p.), with or without pretreatment with 300 mg/kg or 100 mg/kg dabrafenib (p.o.).TUNEL staining for nuclear DNA fragmentation in mouse liver cells.

    Cell Death Dis 2014 5, e1278. Dabrafenib (GSK2118436) purchased from Selleck.

  • Western blot analysis of p-Erk and total ERK in A375 melanoma cell line after treatment with different doses of Dabrafenib for 48 hours (A). p-ERK signal was normalized with total ERK signal (B), SD and means of the normalized p-ERK values were reported.

    PLoS One, 2016, 11(3):e0152104. Dabrafenib (GSK2118436) purchased from Selleck.

Purity & Quality Control

Choose Selective Raf Inhibitors

Biological Activity

Description Dabrafenib (GSK2118436) is a mutant BRAFV600 specific inhibitor with IC50 of 0.8 nM in cell-free assays, with 4- and 6-fold less potency against B-Raf(wt) and c-Raf, respectively.
Targets
B-Raf (V600E) [1]
(Cell-free assay)
B-Raf [1]
(Cell-free assay)
C-Raf [1]
(Cell-free assay)
0.8 nM 3.2 nM 5.0 nM
In vitro

Dabrafenib is selective for Raf kinase, with 400 fold selectivity towards B-Raf over 91% of the other kinases tested. Dabrafenib inhibits B-RafV600E kinase, leading to decreased ERK phosphorylation and inhibition of cell proliferationby an initial arrest in the G1 phase of the cell cycle in cancer cells that specifically encode the mutation for B-RafV600E. [1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MnTYT4lv[XOnIFHzd4F6 M{TVXmlvcGmkaYTpc44hd2ZiTj30[ZJucW6jbDDIbZMhfGGpZ3XkJGIuWmGoIG[2NFBGKG23dHHueEBmgHC{ZYPz[YQhcW5iYnHjeYxwfmm{dYOgbY5n\WO2ZXSgbY5{\WO2IHPlcIx{KGOxLXX4dJJme3OrbnegR2REOzdiYYPz[ZN{\WRiYYOg[IVkemWjc3WgbY4h[mmxdHnufYxifGWmLV3FT{Bxem:2ZXnuJJBpd3OyaH;yfYxifGmxbjDifUBCdHCqYWPjdoVmdiCjc4PhfUB4cXSqIFnDOVAhd2ZiMD6wNFA4KM7:TR?= Mk\LNlQ6ODB4N{O=
SK-MEL-28 MlPJT4lv[XOnIFHzd4F6 NXrZcoRlOSCq NYfkPYJuUW6qaXLpeIlwdiCxZjDCMXJi\iCYNkCwSUBufXSjboSgbY4hcHWvYX6gV2suVUWOLUK4JINmdGy|IHHzd4V{e2WmIHHzJIRm[3KnYYPlJIlvKEWUSzDwbI9{eGixconsZZRqd25id3n0bEBKSzVyIH;mJFAvODB2IN88US=> MVyyOFkxODZ5Mx?=
HepG2 M1vCNGtqdmG|ZTDBd5NigQ>? MmLjTY5pcWKrdHnvckBw\iCELWLh[kBXPjByRTDteZRidnRiaX6gbJVu[W5iSHXwS|Ih[2WubIOgZZN{\XO|ZXSgZZMh\GWlcnXhd4UhcW5iRWLLJJBpd3OyaH;yfYxifGmxbjD3bZRpKEmFNUCgc4YhOC5yMESg{txO MonZNlQ6ODB4N{O=
COLO205 MmrNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1zHZmlvcGmkaYTpc44hd2ZiaIXtZY4hS0:OT{KwOUBk\WyuIIDyc4xq\mW{YYTpc44hf2m2aDDJR|UxKG:oIECuNFA4KM7:TR?= MW[yOFkxODZ5Mx?=
HepG2 M33OWWZ2dmO2aX;uJGF{e2G7 MXe0OUBucW5? NXv5d2FiTE2VTx?= MkHPTY5pcWKrdHnvckBw\iCDbHu1JIlvKFSJRj3i[ZRiNXO2aX31cIF1\WRiaIXtZY4hUGWyR{KgZ4VtdHNiYYPz[ZN{\WRiYYOg[IVkemWjc3WgbY4hW22jZEKgdIhwe3Cqb4L5cIF1cW:wIITy[YF1\WRiZn;yJFQ2KG2rboOgdJJqd3JidH:gWGdHNWKndHGgd5RqdXWuYYTpc44hdWWjc4Xy[YQh[W[2ZYKgOlAhdWmwczDifUBw\Hm|c3X5JIJtd3Ric3Phco5meiCjbnHsfZNqeyC5aYToJGlEPTBib3[gN{44KM7:TR?= M{HhXVI1QTByNkez
HFF MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4jDZVExKM7:TR?= MVS3NkBp MVnEUXNQ M{nPbWlvcGmkaYTpc44hd2ZicILvcIln\XKjdHnvckBw\iCqdX3hckBJTkZiY3XscJMhcGG{Yn;ybY5oKHerbHSgeJlx\SCELWLh[kB4cXSqIFnDOVAhd2ZiMzFOwG0> MVqyN|g1PDB|OB?=
SK-MEL-28 M4PYNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUGxNEDPxE1? M{DhNVczKGh? M3LDUmROW09? MnrBTY5pcWKrdHnvckBw\iCELWLh[kBXPjByRTDteZRidnRvZILpeoVvKFONLV3FUE0zQCClZXzsJJBzd2yrZnXyZZRqd25id3n0bEBKSzVyIH;mJFAvODR|IN88US=> NIDSTlUzOzh2NECzPC=>
A375P-F11 NUjJUpdqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFvrOFIyOCEQvF2= NEHDcFE4OiCq NUW0OItLTE2VTx?= M1\GZ2lvcGmkaYTpc44hd2ZiQj3SZYYhXjZyMFWgcZV1[W62LXTybZZmdiCDM{e1VE1HOTFiY3XscEBxem:uaX\ldoF1cW:wIIfpeIghUUN3MDDv[kAxNjB5MTFOwG0> MkfrNlM5PDRyM{i=
MALME-3M NE\y[WZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWrOS4pkOTBizszN NI\C[5k4OiCq NFLqdIdFVVOR M2jJcGlEPTB;MTDuUS=> M1LnZ|I{QDR2MEO4
UACC-62 NYLuUWJFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXS0THpbOTBizszN NHHnNI84OiCq MU\EUXNQ M{\EOWlEPTB;MTDuUS=> M3PpcVI{QDR2MEO4
C32TG NXLufohwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUSxNEDPxE1? MXG3NkBp NInhUlRFVVOR MoPWTWM2OD1zIH7N NWfDeW5{OjN6NESwN|g>
SK-MEL-1 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWqxNEDPxE1? NIXieo44OiCq NHiwU3VFVVOR NGPy[VlKSzVyPUKgcm0> NEfyOJkzOzh2NECzPC=>
M14 MnWxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{PFN|ExKM7:TR?= Ml7yO|IhcA>? NILNWpJFVVOR M{Dwe2lEPTB;MjDuUS=> NFr2VJUzOzh2NECzPC=>
SK-MEL-28 NXzzW5NsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmjCNVAh|ryP MUC3NkBp NUjXcFBZTE2VTx?= NWTFZnR[UUN3ME2zJI5O Mn;1NlM5PDRyM{i=
A375 NHnoWZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUmxNEDPxE1? MVO3NkBp M3vweWROW09? MWfJR|UxRTRibl2= MW[yN|g1PDB|OB?=
DU-4475 M1zz[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHmyOnYyOCEQvF2= NVr4TJBDPzJiaB?= M4mzbWROW09? M2fXN2lEPTB;NTDuUS=> NX\Le4dmOjN6NESwN|g>
UACC-257 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXixNEDPxE1? NHroZVM4OiCq MmHKSG1UVw>? MoTiTWM2OD14IH7N NX;CbJNkOjN6NESwN|g>
Colo 205 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYSzUnRsOTBizszN NHTlVYQ4OiCq NIriS2lFVVOR NHXEfW5KSzVyPUegcm0> MoG1NlM5PDRyM{i=
SK-MEL-3 NUnrVpNrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEj4blYyOCEQvF2= NHHwT3I4OiCq NHnqUWZFVVOR MUfJR|UxRTdibl2= NVnid3o2OjN6NESwN|g>
SH-4 NE[2VGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWWxNEDPxE1? MnvsO|IhcA>? MonqSG1UVw>? MX\JR|UxRThibl2= M{LwWFI{QDR2MEO4
A101D NISxcGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGnu[JIyOCEQvF2= MWG3NkBp Mmn3SG1UVw>? MmXvTWM2OD17IH7N NVTmc4xxOjN6NESwN|g>
ES-2 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX2xNEDPxE1? NFHsfFc4OiCq MVPEUXNQ MmP5TWM2OD13MzDuUS=> NIntSXYzOzh2NECzPC=>
HT-29 NHvXXINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXuxNEDPxE1? NHzEUWw4OiCq M{ThbmROW09? NIrxdVJKSzVyPU[2JI5O M3HWPFI{QDR2MEO4
SW1417 MmHsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGHnNIwyOCEQvF2= M1vEclczKGh? NIPQWJVFVVOR MWLJR|UxRTF3ODDuUS=> MoPnNlM5PDRyM{i=
SW872 MoXIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFT1W3oyOCEQvF2= M4nWbVczKGh? MXvEUXNQ MUfJR|UxRTN5NzDuUS=> NUP4dpVLOjN6NESwN|g>
RKO MojES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7CXpUyOTBizszN NF7HTmI4OiCq NYLGSHdkTE2VTx?= NXjBeIFmUUN3ME2yMlUzOiEQvF2= NFKxRZAzOzh2NECzPC=>
A673 NV36[IE4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWSxNEDPxE1? M4jkdFczKGh? MkTUSG1UVw>? MorqTWM2OD1zMDFOwG0> MYKyN|g1PDB|OB?=
GCT NIDj[XVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\QXZFLOTBizszN NGPhenM4OiCq NWruUpVyTE2VTx?= MnLqTWM2OD1zMDFOwG0> MV[yN|g1PDB|OB?=
WM-115 NXrOV|J{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4S1c|ExKM7:TR?= MlPKO|IhcA>? NUXOd5JlTE2VTx?= MkTUTWM2OD13IH7N M4rmcFI{QDR2MEO4
YUMAC NIL0flFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3XYbVExKM7:TR?= NYnUbXpvPzJiaB?= NHnHeXlFVVOR NF\jNIRKSzVyPUWgcm0> M4LyNVI{QDR2MEO4
OV-90 NHfrT2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M13XfVExKM7:TR?= NHzNW204OiCq NG\vVnJFVVOR M3LuVmlEPTB;Mkmgcm0> NX\3WJR4OjN6NESwN|g>
NCI-H508 MmjHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkD1NVAh|ryP MkDKO|IhcA>? NGTKT3NFVVOR NV7IOZN1UUN3ME2xNEDPxE1? Mn7FNlM5PDRyM{i=
MDA-MB-231 Mk\KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFXE[HgyOCEQvF2= NIHuWWY4OiCq MonvSG1UVw>? NEPVT3BKSzVyPUGwJO69VQ>? MXyyN|g1PDB|OB?=
SW756 NETXZoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFy0OWwyOCEQvF2= M1H3d|czKGh? NYj5e4JPTE2VTx?= NV;JVG9JUUN3ME2xNEDPxE1? M4fqVFI{QDR2MEO4
SW-837 NHPh[5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUmxNEDPxE1? M4GzcVczKGh? MkLuSG1UVw>? M17Bd2lEPTB;MUCg{txO M1y1cFI{QDR2MEO4
UMUC-3 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4jKUVExKM7:TR?= MnTkO|IhcA>? MlnYSG1UVw>? MWrJR|UxRTFyIN88US=> NGSy[GszOzh2NECzPC=>
LS-174T NWjn[5RFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFL1[lQyOCEQvF2= NHL1U5k4OiCq MYnEUXNQ MVTJR|UxRTFyIN88US=> MWKyN|g1PDB|OB?=
A549 Mmj5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVixNEDPxE1? MnrXO|IhcA>? MX;EUXNQ MXTJR|UxRTFyIN88US=> NGPxOngzOzh2NECzPC=>
SHP-77 NFnVUGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Moi1NVAh|ryP NGHCbnI4OiCq M1;aPGROW09? MW\JR|UxRTFyIN88US=> M4S3e|I{QDR2MEO4
SW480 M2fmVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWGxNEDPxE1? NGra[3o4OiCq NH3jS2hFVVOR NWXoZWs{UUN3ME2xNEDPxE1? MV[yN|g1PDB|OB?=
DLD-1 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkS1NVAh|ryP MVG3NkBp MnLaSG1UVw>? M3vTVmlEPTB;MUCg{txO M1G5dFI{QDR2MEO4
HCT-116 NVLKfZZET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGjudYsyOCEQvF2= NUDJU2FFPzJiaB?= MnLWSG1UVw>? Ml[1TWM2OD1zMDFOwG0> M3TnUlI{QDR2MEO4
NCI-H747 MnLUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnv5NVAh|ryP NEXuelE4OiCq MknDSG1UVw>? MoLoTWM2OD1zMDFOwG0> NXzBOmJMOjN6NESwN|g>
T-84 M{fJU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mkf6NVAh|ryP MnS4O|IhcA>? NH\4dZNFVVOR M3z0XWlEPTB;MUCg{txO M1\QVVI{QDR2MEO4
NCI-H460 M4G0Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUKxNEDPxE1? NXLOc|VjPzJiaB?= NX;zPY5uTE2VTx?= NVXmdllbUUN3ME2xNEDPxE1? NV3mc|VZOjN6NESwN|g>
Calu-6 MmPBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3SyXFExKM7:TR?= MXe3NkBp M{jWTmROW09? NVqzPJV4UUN3ME2xNEDPxE1? M4nCSFI{QDR2MEO4
HCC-2998 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NICyZowyOCEQvF2= M4rPRVczKGh? M2nGW2ROW09? Mk[2TWM2OD1zMDFOwG0> NXr5cVBkOjN6NESwN|g>
LS1034 NV7B[|JzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH;4VY8yOCEQvF2= NVXHRWJLPzJiaB?= NVPtbmV5TE2VTx?= MWDJR|UxRTFyIN88US=> NWrJSYVZOjN6NESwN|g>
CHP-212 M{ftcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWOxNEDPxE1? NUTZTGQ2PzJiaB?= NVm3eVM3TE2VTx?= MXHJR|UxRTFyIN88US=> M1e0dVI{QDR2MEO4
SK-N-AS MmPFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4exbVExKM7:TR?= MVm3NkBp MnXKSG1UVw>? MnK4TWM2OD1zMDFOwG0> M4TjSFI{QDR2MEO4
BFTC-905 NYXoSpZET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVjvTWhSOTBizszN NYL2bmdNPzJiaB?= NECy[XZFVVOR NIixc2VKSzVyPUGwJO69VQ>? NHrEbVczOzh2NECzPC=>
HuT78 NVz1NHh5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1jCZ|ExKM7:TR?= MnnqO|IhcA>? MX3EUXNQ MkfUTWM2OD13MjDuUS=> M1LYXlI{QDR2MEO4
RPMI-8226 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXi2enBROTBizszN NV\zeY9NPzJiaB?= NI[zdoNFVVOR M3\CWGlEPTB;Mk[zJI5O NXLLdVRKOjN6NESwN|g>
BC-3 NYi2[nV[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIrxbpkyOCEQvF2= M3fPdFczKGh? NXXnPYV7TE2VTx?= NUX0[WdGUUN3ME2yO|chdk1? M1TLW|I{QDR2MEO4
ACHN MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4TLVVExKM7:TR?= NWi5bplGPzJiaB?= M3zobWROW09? M2TF[mlEPTB;Mkm0JI5O Mmm3NlM5PDRyM{i=
JRT3-T35 M3TyPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYO3OGt7OTBizszN NYDme5g4PzJiaB?= MX;EUXNQ M{TSV2lEPTB;Mkm1JI5O MlnxNlM5PDRyM{i=
SK-MES-1 MkT2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHTVVmYyOCEQvF2= Mnf2O|IhcA>? M1\NR2ROW09? NGK5SnJKSzVyPUOyPUBvVQ>? MlPGNlM5PDRyM{i=
CESS NYfrU3R1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkLYNVAh|ryP NHz1eZE4OiCq M3vFUmROW09? Ml7CTWM2OD12OUegcm0> NUmyUGQ3OjN6NESwN|g>
H4 Ml7ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYexNEDPxE1? MWG3NkBp Mn7NSG1UVw>? M2K2R2lEPTB;NkG5JI5O M3m1cVI{QDR2MEO4
BC-1 M1vEW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIrKRZkyOCEQvF2= NWPQSnMxPzJiaB?= Mk\RSG1UVw>? NGTUdJNKSzVyPUewOEBvVQ>? NF;aWmMzOzh2NECzPC=>
DB MlLSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWOxNEDPxE1? MV[3NkBp NYP1V4xZTE2VTx?= MVrJR|UxRTh5MzDuUS=> NFy1PFIzOzh2NECzPC=>
RPMI-6666 NEDzOnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4nBeFExKM7:TR?= NX7QPXh3PzJiaB?= NXPqZ3JyTE2VTx?= NYXGdmU{UUN3ME25Nlghdk1? MnrINlM5PDRyM{i=
MC/CAR MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnzyNVAh|ryP NELrPYQ4OiCq M2OxfGROW09? MULJR|UxRTFwMECyJO69VQ>? NXriZXNCOjN6NESwN|g>
SNU-1 Mln4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4nHbFExKM7:TR?= NHzr[o44OiCq NGjLNXRFVVOR NX\PfmZrUUN3ME2xMlUxOSEQvF2= MWeyN|g1PDB|OB?=
CEM/C1 NVnMcop2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXSxNEDPxE1? MnTuO|IhcA>? NXX6T28xTE2VTx?= MmHMTWM2OD1zLke3N{DPxE1? MmGxNlM5PDRyM{i=
GDM-1 NVfwbHQ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoPhNVAh|ryP MU[3NkBp NXvPco1wTE2VTx?= M4S4cWlEPTB;MT65PVch|ryP NXXnSZJyOjN6NESwN|g>
HT-1080 MmTDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGXLfVUyOCEQvF2= NHrzOGo4OiCq MUnEUXNQ NIPQNY1KSzVyPUKuNFA1KM7:TR?= Mn3XNlM5PDRyM{i=
HL-60 MlHvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1r3WlExKM7:TR?= NIqzdGE4OiCq MXTEUXNQ NUHVZ3Q1UUN3ME2yMlE4QCEQvF2= M2KzclI{QDR2MEO4
C3A M2q2fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEPqSowyOCEQvF2= MX[3NkBp MVzEUXNQ MXHJR|UxRTVwNEG0JO69VQ>? Ml7aNlM5PDRyM{i=
MES-SA MlHBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXX6eXpwOTBizszN NIjlT5g4OiCq Ml[0SG1UVw>? M4TFZWlEPTB;Nj65PFkh|ryP M{m0SlI{QDR2MEO4
22Rv1 NH7oRmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{DB[VExKM7:TR?= Mk[3O|IhcA>? NW\TVG9tTE2VTx?= NX[1emZpUUN3ME2xNEDPxE1? MXuyN|g1PDB|OB?=
647-V M2TEeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWGxNEDPxE1? NGOzfZQ4OiCq M1rXbGROW09? NWLDdYpIUUN3ME2xNEDPxE1? MXqyN|g1PDB|OB?=
786-O MkDyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4K5PVExKM7:TR?= M4XNOVczKGh? NHzEUHlFVVOR NFrzW3lKSzVyPUGwJO69VQ>? MViyN|g1PDB|OB?=
A172 M2Dsemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUWxNEDPxE1? MVK3NkBp M1j6SGROW09? MmjuTWM2OD1zMDFOwG0> NFTpdo0zOzh2NECzPC=>
A204 Mm\FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXexNEDPxE1? Mly2O|IhcA>? NVfw[XdTTE2VTx?= M33LNmlEPTB;MUCg{txO MYSyN|g1PDB|OB?=
A427 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXPZVoR5OTBizszN MXu3NkBp NVvrcWpTTE2VTx?= M1T3TGlEPTB;MUCg{txO NUi3UnpuOjN6NESwN|g>
A431 NEnIdnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWnHNXRLOTBizszN MYO3NkBp M4jpPGROW09? NV;YfWtHUUN3ME2xNEDPxE1? NV7YXHBDOjN6NESwN|g>
A2780 M2rR[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnHXNVAh|ryP NHz1cXM4OiCq M{LQeWROW09? MojJTWM2OD1zMDFOwG0> MYSyN|g1PDB|OB?=
ARH-77 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHK0Z|gyOCEQvF2= M1fQb|czKGh? MWHEUXNQ MkT0TWM2OD1zMDFOwG0> MlnDNlM5PDRyM{i=
Be(2)C MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHeyVJIyOCEQvF2= NFXVU2g4OiCq MnztSG1UVw>? M1HVRmlEPTB;MUCg{txO NWH5fItmOjN6NESwN|g>
BT-20 MnjHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml;tNVAh|ryP M1XDeVczKGh? M{P3cWROW09? MVXJR|UxRTFyIN88US=> MYeyN|g1PDB|OB?=
BxPc3 NWLpNWQ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnrYNVAh|ryP MWe3NkBp NVrVR5duTE2VTx?= MlTDTWM2OD1zMDFOwG0> MUeyN|g1PDB|OB?=
C-4 I NEnaZXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3zWXlExKM7:TR?= M3fIOVczKGh? MYjEUXNQ MUXJR|UxRTFyIN88US=> M1TLVFI{QDR2MEO4
C33A NYjkN5lQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2q5V|ExKM7:TR?= NGO0R|g4OiCq MX\EUXNQ NX7UWnp7UUN3ME2xNEDPxE1? MUWyN|g1PDB|OB?=
CAL-27 MmLGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFThbIYyOCEQvF2= MXW3NkBp M4rtOmROW09? NITPUpVKSzVyPUGwJO69VQ>? MUiyN|g1PDB|OB?=
CAL-62 Mn;OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWSwdldsOTBizszN NWi3ZmVWPzJiaB?= MkLhSG1UVw>? MXLJR|UxRTFyIN88US=> NHTqW5YzOzh2NECzPC=>
Calu-3 NX;ySoJFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV3NOphuOTBizszN NEHu[Ho4OiCq Mom4SG1UVw>? NGnTe4hKSzVyPUGwJO69VQ>? MVuyN|g1PDB|OB?=
CaOV3 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmLUNVAh|ryP MnTqO|IhcA>? NFS5emVFVVOR M{jx[GlEPTB;MUCg{txO NFv4XHMzOzh2NECzPC=>
CGTHW1 NHXpNolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWexbm1FOTBizszN MUi3NkBp MYfEUXNQ MkfFTWM2OD1zMDFOwG0> NVjxSYJ{OjN6NESwN|g>
CHL-1 M{Hj[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIHkZ|gyOCEQvF2= Ml7IO|IhcA>? NHnhVldFVVOR MV;JR|UxRTFyIN88US=> NVyyZnlsOjN6NESwN|g>
Colo320DM MmnhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M33hOVExKM7:TR?= M3fNOFczKGh? MlvySG1UVw>? NGLaVmZKSzVyPUGwJO69VQ>? Mn3kNlM5PDRyM{i=
Colo704 M4T3e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGrXUHgyOCEQvF2= MUi3NkBp MlrZSG1UVw>? MWPJR|UxRTFyIN88US=> NYrlfJprOjN6NESwN|g>
COR-L23 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFy0XJgyOCEQvF2= MmPTO|IhcA>? NV:yUGhxTE2VTx?= M1;V[WlEPTB;MUCg{txO Mo\qNlM5PDRyM{i=
CRO-AP2 M1jCdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnvYNVAh|ryP M1:2[FczKGh? NFLWO4tFVVOR NFTyWWlKSzVyPUGwJO69VQ>? M4DYdFI{QDR2MEO4
Daudi Ml7ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVywd4ZGOTBizszN NVHzTohzPzJiaB?= MXjEUXNQ MYLJR|UxRTFyIN88US=> NEm0[3AzOzh2NECzPC=>
DOTC 24510 M1HYfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3TzeVExKM7:TR?= M{jYe|czKGh? NUjEZ3d1TE2VTx?= MULJR|UxRTFyIN88US=> NGDnWJMzOzh2NECzPC=>
DU-145 NFrMcZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoD1NVAh|ryP NVW2T2Z{PzJiaB?= MXnEUXNQ Mk\kTWM2OD1zMDFOwG0> NULLZWVIOjN6NESwN|g>
EB-3 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWSxNEDPxE1? MYm3NkBp NHi5ZlhFVVOR MmfJTWM2OD1zMDFOwG0> MYqyN|g1PDB|OB?=
EFM-19 NIT2ZXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3TwZVExKM7:TR?= Mle1O|IhcA>? Mn\WSG1UVw>? M1nhR2lEPTB;MUCg{txO M4f4clI{QDR2MEO4
EKVX MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIXlcYIyOCEQvF2= MlfOO|IhcA>? M{fuZmROW09? M1\uN2lEPTB;MUCg{txO MYGyN|g1PDB|OB?=
FaDu M3Hwb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVzrcJh1OTBizszN MXO3NkBp NGjFWJFFVVOR M3\L[GlEPTB;MUCg{txO MkT2NlM5PDRyM{i=
G401 NHLFe|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYqxNEDPxE1? NHzCPIw4OiCq NH\SZ3BFVVOR MoLmTWM2OD1zMDFOwG0> M12wcVI{QDR2MEO4
HCC-70 MmHpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVmxNEDPxE1? M{T5WVczKGh? MV7EUXNQ MXrJR|UxRTFyIN88US=> MWKyN|g1PDB|OB?=
HCC-1954 M4LGZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY[xNEDPxE1? NEf4c4Y4OiCq NXXXeGlLTE2VTx?= NI\GdW5KSzVyPUGwJO69VQ>? M1HEUVI{QDR2MEO4
Hela MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXexNEDPxE1? MlTNO|IhcA>? M{XYWGROW09? MVTJR|UxRTFyIN88US=> MmrQNlM5PDRyM{i=
Hep3B MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIjOco8yOCEQvF2= MVe3NkBp NHHCV3ZFVVOR NGT3SnVKSzVyPUGwJO69VQ>? NVXZbXlQOjN6NESwN|g>
HMCB NXPMfGR7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M16yN|ExKM7:TR?= NF\SW3Q4OiCq M4HSNGROW09? MYDJR|UxRTFyIN88US=> M2nNSFI{QDR2MEO4
HN5 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXrURnloOTBizszN M4P4c|czKGh? NUixXJVyTE2VTx?= NIrrb5lKSzVyPUGwJO69VQ>? MljMNlM5PDRyM{i=
HOS NUTJXYIzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1XFOFExKM7:TR?= MnHOO|IhcA>? M3;lZWROW09? MnvXTWM2OD1zMDFOwG0> M{XCUFI{QDR2MEO4
HPAF-II MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXKxNEDPxE1? MlzJO|IhcA>? MojuSG1UVw>? M{DHUWlEPTB;MUCg{txO MVOyN|g1PDB|OB?=
Hs746.T NWrYUZZ7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4\5b|ExKM7:TR?= MXS3NkBp MkjESG1UVw>? NEmyRZBKSzVyPUGwJO69VQ>? MV:yN|g1PDB|OB?=
HT NXLGW4NYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4mweVExKM7:TR?= NIfTfXo4OiCq MkPWSG1UVw>? MYnJR|UxRTFyIN88US=> NX;RUmU{OjN6NESwN|g>
HT-3 NFn3N3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnvWNVAh|ryP M{TKelczKGh? NWPmOnZ[TE2VTx?= NVfBeFhJUUN3ME2xNEDPxE1? M3zKRlI{QDR2MEO4
HuNS-1 NHf0TYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHv2Um0yOCEQvF2= NHXYSZg4OiCq Mnj3SG1UVw>? MXXJR|UxRTFyIN88US=> NVLK[ohvOjN6NESwN|g>
IGROV1 MnW5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnWwNVAh|ryP M{HoNVczKGh? M3XjW2ROW09? NEP4PFFKSzVyPUGwJO69VQ>? M2TYW|I{QDR2MEO4
J82 NV:5NotPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoCzNVAh|ryP NWjxXopUPzJiaB?= MojaSG1UVw>? NF62PXVKSzVyPUGwJO69VQ>? NYfOco5KOjN6NESwN|g>
JM1 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\xPFExKM7:TR?= M4[4TVczKGh? MkK3SG1UVw>? NVLDcGFpUUN3ME2xNEDPxE1? M4K1Z|I{QDR2MEO4
Kato III NHfpbndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIjBN5QyOCEQvF2= MmrHO|IhcA>? NGLSc5pFVVOR NImzRXRKSzVyPUGwJO69VQ>? NXn6W3VWOjN6NESwN|g>
KHOS-240S MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M374NlExKM7:TR?= NGW5[os4OiCq M{Lqb2ROW09? MWTJR|UxRTFyIN88US=> MmnPNlM5PDRyM{i=
KM-12 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MY[xNEDPxE1? NY\JVHBGPzJiaB?= NVPafWJnTE2VTx?= MYrJR|UxRTFyIN88US=> M{Hob|I{QDR2MEO4
KPL-1 Mmr5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWXnbZRmOTBizszN MUC3NkBp MX\EUXNQ M2KxZWlEPTB;MUCg{txO NFzzSlMzOzh2NECzPC=>
KYSE-30 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXvwcGk5OTBizszN NVzOPXVyPzJiaB?= NGfBbWJFVVOR NIjrbG9KSzVyPUGwJO69VQ>? MmjCNlM5PDRyM{i=
LNCaP MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWKxNEDPxE1? NVGwZ|BwPzJiaB?= NUPIOYF2TE2VTx?= MmjCTWM2OD1zMDFOwG0> MUiyN|g1PDB|OB?=
MCF-7 NHvRV2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHrGXHgyOCEQvF2= MXm3NkBp NHL6[plFVVOR NUj3Z2t6UUN3ME2xNEDPxE1? NV;ISYFoOjN6NESwN|g>
MC-IXC MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3HxOVExKM7:TR?= MXm3NkBp NHvJdYFFVVOR MUPJR|UxRTFyIN88US=> M2j3[FI{QDR2MEO4
MDA-MB-175 VII MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWCxNEDPxE1? MlKwO|IhcA>? M3LhfmROW09? MV7JR|UxRTFyIN88US=> MmfzNlM5PDRyM{i=
MDA-MB-468 MlLvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVSxNEDPxE1? M4TUflczKGh? NXzPc4c{TE2VTx?= NXnzbpJsUUN3ME2xNEDPxE1? NYrMZoJbOjN6NESwN|g>
MiaPaCa NUCxRo5PT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M136NVExKM7:TR?= NGnLdlg4OiCq NXznZo1CTE2VTx?= M4LoRWlEPTB;MUCg{txO NE\QUGEzOzh2NECzPC=>
Molt-4 NFywboJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlLENVAh|ryP NYfPdlRTPzJiaB?= M1PTR2ROW09? M1n3V2lEPTB;MUCg{txO NVP6OphtOjN6NESwN|g>
NCI-ADR/RES M37NXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{S2bVExKM7:TR?= MX[3NkBp NV7mcmhkTE2VTx?= Mo\xTWM2OD1zMDFOwG0> NYHjR45oOjN6NESwN|g>
NCI-H69 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\6bVdJOTBizszN NYrMUpNOPzJiaB?= MmXqSG1UVw>? Mn3DTWM2OD1zMDFOwG0> M2DRTFI{QDR2MEO4
NCI-H82 M4T4VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4KyV|ExKM7:TR?= Mn\jO|IhcA>? NIjqc5VFVVOR MVLJR|UxRTFyIN88US=> MmHrNlM5PDRyM{i=
NCI-N87 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Moq1NVAh|ryP Mmn4O|IhcA>? MWHEUXNQ MWjJR|UxRTFyIN88US=> MV6yN|g1PDB|OB?=
NCI-H146 NUPw[pV7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4niN|ExKM7:TR?= Mk\TO|IhcA>? MXjEUXNQ MoP4TWM2OD1zMDFOwG0> NXftTpVWOjN6NESwN|g>
NCI-H157 MnLOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXyxSYFTOTBizszN M{\H[lczKGh? MYDEUXNQ MkXMTWM2OD1zMDFOwG0> MW[yN|g1PDB|OB?=
NCI-H187 NVjvPGJOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlnZNVAh|ryP M3qzVFczKGh? MnvnSG1UVw>? M{DHVGlEPTB;MUCg{txO MUeyN|g1PDB|OB?=
NCI-H209 NU\1WVFST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYXZN5RrOTBizszN MWC3NkBp NVK0Z|NWTE2VTx?= NXvhVYZyUUN3ME2xNEDPxE1? M3zS[|I{QDR2MEO4
NCI-H226 NUTpbJFPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnnPNVAh|ryP MUi3NkBp NEWwO29FVVOR NFLXcZNKSzVyPUGwJO69VQ>? NInBU5gzOzh2NECzPC=>
NCI-H292 M2HGRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{DIXlExKM7:TR?= M2e1ZVczKGh? M1PqNWROW09? NGLHbYdKSzVyPUGwJO69VQ>? M3HEb|I{QDR2MEO4
NCI-H322 MofvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1\ZV|ExKM7:TR?= NXnoT4lNPzJiaB?= NYDkeFhJTE2VTx?= MYDJR|UxRTFyIN88US=> MXeyN|g1PDB|OB?=
NCI-H358 Mn;4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFLiVFUyOCEQvF2= M{TPXVczKGh? NUnGWYhDTE2VTx?= NVnSbGRYUUN3ME2xNEDPxE1? MVeyN|g1PDB|OB?=
NCI-H520 MlXmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnH0NVAh|ryP NXLEOXVmPzJiaB?= MVvEUXNQ M2XjbWlEPTB;MUCg{txO MYiyN|g1PDB|OB?=
NCI-H526 NHjKfY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2nxTVExKM7:TR?= NFf5Z3c4OiCq NG\xcI1FVVOR NX72WGJ2UUN3ME2xNEDPxE1? NVfwR3V7OjN6NESwN|g>
NCI-H630 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHHWcmIyOCEQvF2= NF7KVIU4OiCq MVrEUXNQ MVLJR|UxRTFyIN88US=> NHexSo0zOzh2NECzPC=>
NCI-H661 M1jqOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEDDOlEyOCEQvF2= MV:3NkBp NGnncolFVVOR M2DofGlEPTB;MUCg{txO NX;WNG5wOjN6NESwN|g>
NCI-H716 NGTQcIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWrXVlQ3OTBizszN NWj3bVZmPzJiaB?= NWfL[It[TE2VTx?= MYHJR|UxRTFyIN88US=> NUTjXnZ{OjN6NESwN|g>
NCI-H1563 NILRSZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn\jNVAh|ryP NFu4Now4OiCq NWPy[WdQTE2VTx?= NXz2TJRsUUN3ME2xNEDPxE1? M4\mPVI{QDR2MEO4
NCI-H1792 M1fXdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\UNVAh|ryP M1rVU|czKGh? NITydZpFVVOR M1nOXGlEPTB;MUCg{txO Ml75NlM5PDRyM{i=
NCI-H2030 NXv0d3B[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnLwNVAh|ryP NV6zVHZpPzJiaB?= NYL4UIlDTE2VTx?= NIrqe5ZKSzVyPUGwJO69VQ>? MYqyN|g1PDB|OB?=
NCI-H2052 NGLmeGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGD3XZEyOCEQvF2= NUfofXV[PzJiaB?= NX;ycodLTE2VTx?= NWjJS2RxUUN3ME2xNEDPxE1? NI\KfmozOzh2NECzPC=>
NCI-H2122 M{nWOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXzJVmNuOTBizszN NHrXepI4OiCq MXzEUXNQ NIjocpVKSzVyPUGwJO69VQ>? MXWyN|g1PDB|OB?=
NCI-H2228 M2rpfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn3SNVAh|ryP Mmi0O|IhcA>? MnzrSG1UVw>? MWTJR|UxRTFyIN88US=> MoLVNlM5PDRyM{i=
OE-19 M33zcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4fGNFExKM7:TR?= MWG3NkBp NImy[ppFVVOR M3;SdmlEPTB;MUCg{txO MWCyN|g1PDB|OB?=
OE-21 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M33FWVExKM7:TR?= NYfMOXpxPzJiaB?= MWjEUXNQ NX33[lI3UUN3ME2xNEDPxE1? MVKyN|g1PDB|OB?=
OE-33 NWjFSXVvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHza[IkyOCEQvF2= MofQO|IhcA>? MWfEUXNQ MnPGTWM2OD1zMDFOwG0> NIrJWZkzOzh2NECzPC=>
OVCAR-3 MoC2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHvaPZUyOCEQvF2= M4HGNVczKGh? M{HjTmROW09? NIfDTJlKSzVyPUGwJO69VQ>? NGf5eIkzOzh2NECzPC=>
OVCAR-4 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkTHNVAh|ryP NXf1SVZsPzJiaB?= MVPEUXNQ MmfETWM2OD1zMDFOwG0> M17TZVI{QDR2MEO4
OVCAR-5 M3XUdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmO0NVAh|ryP MUG3NkBp NUXkVIV6TE2VTx?= NH\YbVZKSzVyPUGwJO69VQ>? NWjtS|A5OjN6NESwN|g>
P3HR-1 MlewS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml7LNVAh|ryP MkDZO|IhcA>? MWPEUXNQ NHHaRoFKSzVyPUGwJO69VQ>? NWHPVlFvOjN6NESwN|g>
PC-3 NFzaPZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWK1V5ZSOTBizszN MV23NkBp M3vWcmROW09? NVT5c5VEUUN3ME2xNEDPxE1? MmnaNlM5PDRyM{i=
Raji M4HIcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFv3TJoyOCEQvF2= Mo\XO|IhcA>? MmrZSG1UVw>? NVywNnR3UUN3ME2xNEDPxE1? MmDSNlM5PDRyM{i=
RD MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWqxNEDPxE1? NUC4UolTPzJiaB?= NWHHdFZZTE2VTx?= NGn2WpdKSzVyPUGwJO69VQ>? NIntZ5QzOzh2NECzPC=>
RD-ES MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnq2NVAh|ryP MWe3NkBp NUj2RY9JTE2VTx?= NHf2SoFKSzVyPUGwJO69VQ>? NFjkcIMzOzh2NECzPC=>
RL MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGL0VlEyOCEQvF2= MUi3NkBp MX7EUXNQ M1vrRmlEPTB;MUCg{txO NGXke|AzOzh2NECzPC=>
SaOS2 M3\GUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo\wNVAh|ryP NVP1[4dsPzJiaB?= M1;pXWROW09? M{\iVmlEPTB;MUCg{txO MYSyN|g1PDB|OB?=
SCC-9 NIjQSpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXewbHNuOTBizszN NWPYdmVoPzJiaB?= M1vieWROW09? NHrHOXlKSzVyPUGwJO69VQ>? MYWyN|g1PDB|OB?=
SCC-12 NHjiTYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVznZosyOTBizszN NUi2WWoyPzJiaB?= MVrEUXNQ NULBZW1XUUN3ME2xNEDPxE1? M2j1flI{QDR2MEO4
SCC-13 NEDV[5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2Dqc|ExKM7:TR?= MX63NkBp MVjEUXNQ MnH2TWM2OD1zMDFOwG0> M2XCclI{QDR2MEO4
SCC-15 M3zlZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVXudWdjOTBizszN M1LrfVczKGh? MX\EUXNQ NFzyU|VKSzVyPUGwJO69VQ>? NHrROW0zOzh2NECzPC=>
SCC-25 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHHQcZcyOCEQvF2= MVq3NkBp M{XpXGROW09? NWnZZmt2UUN3ME2xNEDPxE1? MnrTNlM5PDRyM{i=
SCLC-3 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGHyS2QyOCEQvF2= NGHnRYs4OiCq MULEUXNQ MlvFTWM2OD1zMDFOwG0> MYeyN|g1PDB|OB?=
SF-268 NWrVVFhiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGPYc|QyOCEQvF2= NVWxTJl6PzJiaB?= NWLCbG9[TE2VTx?= NFzDTVNKSzVyPUGwJO69VQ>? NXniS4c1OjN6NESwN|g>
SF-295 NGHB[|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUexNEDPxE1? MmDWO|IhcA>? MlXwSG1UVw>? Mn7VTWM2OD1zMDFOwG0> NH;IPZozOzh2NECzPC=>
SJRH30 M3u2SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUmxNEDPxE1? NIjWUnQ4OiCq M1HLd2ROW09? MXnJR|UxRTFyIN88US=> NWHqelBGOjN6NESwN|g>
SK-BR-3 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWf5O5F7OTBizszN MX[3NkBp NEnsXlNFVVOR M4fONGlEPTB;MUCg{txO MVWyN|g1PDB|OB?=
SK-LMS-1 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mmq1NVAh|ryP M{HkVFczKGh? MlPGSG1UVw>? NF;CNlBKSzVyPUGwJO69VQ>? NH2wOowzOzh2NECzPC=>
SK-N-DZ MlfVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIftZmUyOCEQvF2= NVi0VnBPPzJiaB?= NXXQb5lbTE2VTx?= NGfQ[4ZKSzVyPUGwJO69VQ>? M2rzZVI{QDR2MEO4
SK-N-F1 NF;PV2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWqxNEDPxE1? NFz6VZQ4OiCq NF7O[plFVVOR NVPSV2ExUUN3ME2xNEDPxE1? NWjIOYJ{OjN6NESwN|g>
SKOV-3 NITmVGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{fr[lExKM7:TR?= NULjTXB3PzJiaB?= NXvNNYpoTE2VTx?= M4jUSWlEPTB;MUCg{txO NXuyRYJ[OjN6NESwN|g>
SK-UT-1 M1[4cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NITz[lkyOCEQvF2= M4fhV|czKGh? MnH4SG1UVw>? MmPxTWM2OD1zMDFOwG0> NF3vNJozOzh2NECzPC=>
SN12C MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{f3cFExKM7:TR?= NUPSdGRKPzJiaB?= M3LxNGROW09? M4\GdWlEPTB;MUCg{txO NVz1boF{OjN6NESwN|g>
SNB-19 NYfDbZZ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVOxNEDPxE1? M3XrdVczKGh? MX\EUXNQ MmDXTWM2OD1zMDFOwG0> Ml;qNlM5PDRyM{i=
SNU-5 M1zue2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4mzclExKM7:TR?= NGfoRZc4OiCq MWHEUXNQ MV\JR|UxRTFyIN88US=> M1n1[VI{QDR2MEO4
SNU-16 NYL0fYZXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2Dld|ExKM7:TR?= NFrQO204OiCq MYnEUXNQ MXrJR|UxRTFyIN88US=> NH;CdnYzOzh2NECzPC=>
SNU-398 NGLDe4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXXGO5FTOTBizszN NX3HT5RVPzJiaB?= NHr1W2xFVVOR NXT3OWMxUUN3ME2xNEDPxE1? M4X3e|I{QDR2MEO4
SNU-449 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkDINVAh|ryP NGDSN3Y4OiCq MnnNSG1UVw>? MlriTWM2OD1zMDFOwG0> NHHndI4zOzh2NECzPC=>
SR MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVu3OY9LOTBizszN MW[3NkBp NGLNWnhFVVOR NGXmNpNKSzVyPUGwJO69VQ>? NX\Y[mV3OjN6NESwN|g>
ST486 M2HMd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXKxNEDPxE1? MmC1O|IhcA>? M1jz[mROW09? NWHJ[2ZmUUN3ME2xNEDPxE1? M4jP[lI{QDR2MEO4
SW579 NVnkR3NWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlGwNVAh|ryP MnzxO|IhcA>? NGDuOXFFVVOR MV3JR|UxRTFyIN88US=> MV2yN|g1PDB|OB?=
SW684 MkG3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV\TNGJKOTBizszN NYjrTXZbPzJiaB?= M3WyWGROW09? NWfxO4d6UUN3ME2xNEDPxE1? M3jKZlI{QDR2MEO4
SW-780 NFzyWWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGPW[5kyOCEQvF2= MlP3O|IhcA>? M17GPGROW09? NXezXYJuUUN3ME2xNEDPxE1? MVmyN|g1PDB|OB?=
SW900 NEfUU4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYixNEDPxE1? MYS3NkBp MWDEUXNQ MYDJR|UxRTFyIN88US=> Mnr6NlM5PDRyM{i=
SW1088 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUSxNEDPxE1? MkXNO|IhcA>? MWHEUXNQ NGHsW2VKSzVyPUGwJO69VQ>? NHnveGkzOzh2NECzPC=>
SW1463 NYf6OHBjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXWxNEDPxE1? NXKydJFsPzJiaB?= M{TYcmROW09? NXvMeJRzUUN3ME2xNEDPxE1? MkjvNlM5PDRyM{i=
SW1990 NF3Sd5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnrzNVAh|ryP NH7te5A4OiCq MWLEUXNQ MlP1TWM2OD1zMDFOwG0> NHnwOG4zOzh2NECzPC=>
T47D Ml\rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVuxNEDPxE1? NGHwbGY4OiCq Mo\kSG1UVw>? MV\JR|UxRTFyIN88US=> NGDxPZgzOzh2NECzPC=>
TE381.T NFHmS3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXjTNpN[OTBizszN NH;FZm44OiCq MVjEUXNQ MU\JR|UxRTFyIN88US=> NVL1fmdpOjN6NESwN|g>
TK-10 Mm[2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUCxNEDPxE1? NY\xN|JpPzJiaB?= M2GxPGROW09? NUfXVJl{UUN3ME2xNEDPxE1? M4f6VVI{QDR2MEO4
U2OS NEKxOWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1LJOFExKM7:TR?= NV;uco1SPzJiaB?= M1fFV2ROW09? M{iwdmlEPTB;MUCg{txO Mk\ZNlM5PDRyM{i=
U251 NVTaS|lKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYOxNEDPxE1? M3PncVczKGh? NW\mXnhwTE2VTx?= NFHnZ|lKSzVyPUGwJO69VQ>? NFW5RY0zOzh2NECzPC=>
UACC-812 NFn3boNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnqyNVAh|ryP NE\yWm44OiCq M4O1NWROW09? MmjkTWM2OD1zMDFOwG0> NUniUYlLOjN6NESwN|g>
YAPC MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYjlXGFVOTBizszN NY\2eIZrPzJiaB?= NUnUOINVTE2VTx?= M2rzRmlEPTB;MUCg{txO MnvUNlM5PDRyM{i=
ZR-75-1 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVKxNEDPxE1? MkPnO|IhcA>? M2jDXmROW09? Ml:1TWM2OD1zMDFOwG0> M3TLSVI{QDR2MEO4
A375 M4nLfmZ2dmO2aX;uJIF{e2G7 M4DGVlEvOiEQvF2= NH7Kc|Q1KGh? NVm0Om9{TE2VTx?= M4HwR2lvcGmkaYTpc44hd2ZicHjvd5Bpd3K7bHH0bY9vKG:oIF3FT{whTVKNLDDhcoQhWz[S MYmyNlM5QTR5MR?=
YUSIT1 NWCwPGtiTnWwY4Tpc44h[XO|YYm= MnPaSG1UVw>? NUnIdnlzemWmdXPl[EB{\W6|aYTpeol1gSC5aYToJGlEPTBiPjCwMlUh|ryP MkC2NlI{QDl2N{G=
MeWo Mn;NS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MXvEUXNQ NWTJTmZ7UUN3MDC9JFk5PyCwTR?= MoXTNlYxOTh3MkS=
WiDr MoLVS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M4j3[WROW09? NEjsRXJKSzVyIE2gO|Yhdk1? NFvGem0zPjBzOEWyOC=>
Colo-205 MnHTSpVv[3Srb36gZZN{[Xl? MlfUNUDPxE1? NGfWV|Y1KGR? M4jDbWROW09? NWrndmtnUW6mdXPl[EBiKGirZ3jsfUBkd22yYYLhZoxmKGOxbYDhZ5Rqd25icHjlco91gXCn NEfJdmszPTN6MUG1Ni=>
RBW-1 M2q3SmZ2dmO2aX;uJIF{e2G7 NYXEWI1TOSEQvF2= MlroSG1UVw>? NHz2[2VPdyC{ZXT1Z5Rqd25ib3[gUYVsKDFxMjDwbI9{eGixconsZZRqd25? MVWyOFg5PTZ7MB?=
RBO-1 M1TXd2Z2dmO2aX;uJIF{e2G7 MUGxJO69VQ>? MkLPSG1UVw>? NYSxO3pVUW6qaXLpeIlwdiCxZjDN[YshOS9{IIDoc5NxcG:{eXzheIlwdg>? M1vBb|I1QDh3Nkmw
RBO-2 Ml\kSpVv[3Srb36gZZN{[Xl? MljtNUDPxE1? MWrEUXNQ NFLydHpKdmirYnn0bY9vKG:oIDDN[YshOS9{IIDoc5NxcG:{eXzheIlwdg>? NF;QUnMzPDh6NU[5NC=>
RBOW MUjGeY5kfGmxbjDhd5NigQ>? MnLhNUDPxE1? MnLaSG1UVw>? MYfJcohq[mm2aX;uJI9nKCCPZXugNU8zKHCqb4PwbI9zgWyjdHnvci=> MXSyOFg5PTZ7MB?=
M257 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4PSVFExOCCwTR?= NWjUZ5A{PzJiaB?= NGnLW49Fd2W|IH7veEBqdmirYnn0JJBzd2yrZnXyZZRqd25ib3[gUVI2PyClZXzsJIhiemKxdYLpcochf2muZDD0fZBmKEKUQV[= NF;wSlgzOzNzN{S0Oi=>
LCP MoLHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{TH[|ExOCCwTR?= M1fzcFczKGh? MWjJcohq[mm2aX;uJI9nKHC{b3zp[oVz[XSrb36gc4YhVEOSIHPlcIwhcGG{Yn;1dolv\yCEUlHGJHY3ODCUIH31eIFvfGG2aX;u NVuydmh[OjN|MUe0OFY>
WM266 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlnKNVAxKG6P NEPzWlY4OiCq NVHUSnBoUW6qaXLpeIlwdiCxZjDwdo9tcW[ncnH0bY9vKG:oIGfNNlY3KGOnbHygbIFz[m:3cnnu[{BDWkGIIG[2NFFFKG23dHHueIF1cW:w NH;5ZmszOzNzN{S0Oi=>
M257 MmnoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2r4flExOCCwTR?= NIf6WG44OiCq NGH4d4ZFd2W|IH7veEBqdmirYnn0JGVTUzFvMjDwbI9{eGixconsZZRqd25iaX6gUVI2PyClZXzsJIhiemKxdYLpcochf2muZDD0fZBmKEKUQV[= NXj0ZYV1OjN|MUe0OFY>
LCP MlnPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEjiXGkyODBibl2= M4HYfVczKGh? NHrJXmhKdmirYnn0JGVTUzFvMjDwbI9{eGixconsZZRqd25iaX6gUGNRKGOnbHygbIFz[m:3cnnu[{BDWkGIIG[2NFBTKG23dHHueIF1cW:w Mo\2NlM{OTd2NE[=
WM266 MkO0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NELBXJcyODBibl2= MYe3NkBp MkHKTY5pcWKrdDDFVmsyNTJicHjvd5Bpd3K7bHH0bY9vKGmwIGfNNlY3KGOnbHygbIFz[m:3cnnu[{BDWkGIIG[2NFBFKG23dHHueIF1cW:w MnTENlM{OTd2NE[=

... Click to View More Cell Line Experimental Data

In vivo Dabrafenib (orally administrated) inhibits the growth of B-RafV600E mutant melanoma (A375P) and colon cancer (Colo205) human tumor xenografts, growing subcutaneously in immuno-compromised mice. [1]

Protocol

Solubility (25°C)

In vitro DMSO 30 mg/mL (57.74 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents individually and in order:
30% PEG400+0.5% Tween80+5% propylene glycol
8 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 519.56
Formula

C23H20F3N5O2S2

CAS No. 1195765-45-7
Storage powder
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01723202 Active, not recruiting Follicular Thyroid Cancer|Insular Thyroid Cancer|Papillary Thyroid Cancer|Recurrent Thyroid Cancer Manisha Shah|National Comprehensive Cancer Network|Ohio State University Comprehensive Cancer Center November 7, 2012 Phase 2
NCT02672358 Not yet recruiting Non-Small-Cell Lung Cancer Novartis Pharmaceuticals|Novartis October 2017 Phase 2
NCT02447939 Withdrawn Melanoma GlaxoSmithKline May 2017 Phase 1
NCT02967692 Not yet recruiting Melanoma Novartis Pharmaceuticals|Novartis February 2017 Phase 3
NCT02858921 Not yet recruiting Melanoma Melanoma Institute Australia|Merck Sharp & Dohme Corp.|Novartis February 2017 Phase 2
NCT03026517 Recruiting Melanoma Memorial Sloan Kettering Cancer Center|Massachusetts General Hospital|Weill Medical College of Cornell University January 2017 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Raf Signaling Pathway Map

Raf Inhibitors with Unique Features

Related Raf Products

Tags: buy Dabrafenib (GSK2118436) | Dabrafenib (GSK2118436) supplier | purchase Dabrafenib (GSK2118436) | Dabrafenib (GSK2118436) cost | Dabrafenib (GSK2118436) manufacturer | order Dabrafenib (GSK2118436) | Dabrafenib (GSK2118436) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID